Abbott Laboratories Corporation

Other

Ligand Pharmaceuticals, Inc.

Michael J Coghlan

Michael E Kort

James Patrick Edwards

Todd Kevin Jones

Lawrence A Black

Teodozyj Kolasa

Andrew O Stewart

Meena V Patel

Huaqing Liu

Anwer Basha

Jeffrey J Rohde

Catherine M McCarty

Alan X Wang

Philip R Kym

John K Pratt

Jimmie L Moore

Jay R Luly

Steven Elmore

Jeffrey Michael Schkeryantz

Steven W Elmore

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently markered non-steroidal anti-inflammatory drugs (NSAIDs).

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazinone compounds of formula Iwhich are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Compounds having Formula Iare useful for partially or fully antagonizing, repressing, agonizing, or modulating the glucocorticoid receptor and treating immune, autoimmune and inflammatory diseases in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of inhibiting immune or autoimmune diseases in a mammal.

Glucocorticoid-selective anti-inflammatory agents

Glucocortiocoid-selective antinflammatory agents

Glucocortiocoid-selective antiinflammatory agents

The present invention describes pyridazinone compounds of formula I

Compounds having Formula I ##STR1## are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.

Glucocortiocoid-selective agents

Growing community of inventors

Grayslake, IL, United States of America

Michael J Coghlan